Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04559217
Overview
Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.
Sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase
Phase 2
Contacts
Amelie Tetu, MSc
amelie.tetu.ciussse-chus@ssss.gouv.qc.ca
819-346-1110 ext 15571
ClinicalTrials.gov
NCT04559217Help us improve your experience